NCT00896480View on ClinicalTrials.gov

Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 19, 2009

Primary Completion Date

November 3, 2014

Study Completion Date

November 3, 2014

Conditions
Melanoma
Interventions
BIOLOGICAL

Immunotherapeutic GSK2132231A

Administration by intramuscular injection

Trial Locations (8)

1090

GSK Investigational Site, Brussels

1200

GSK Investigational Site, Brussels

2610

GSK Investigational Site, Wilrijk

14033

GSK Investigational Site, Caen

51092

GSK Investigational Site, Reims

59037

GSK Investigational Site, Lille

75475

GSK Investigational Site, Paris

94805

GSK Investigational Site, Villejuif

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY